IMMUNOPHARMACOLOGY Flashcards

1
Q

List 7 different types of immunosuppressive drugs?

A
Glucocorticoids
Calcineurin Inhibitors
Proliferation Signal Inhibitors
Inhibitors of Angiogenesis
Cytotoxic Agents
Other Agents
Immunosuppressive Antibodies
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Glucocorticoids effects and how does it modulate its effects?

A

• Glucocorticoids have broad anti-inflammatory
effects.
• Glucocorticoids act by binding to the cytosolic
glucocorticoid receptor.
• The glucocorticoid-glucocorticoid receptor
complex translocates to the nucleus and binds to
glucocorticoid response elements (GREs) in the
promoter region of specific genes, either upregulating or down-regulating gene expression
• Glucocorticoids down-regulate the expression
of many inflammatory mediators.
• The overall effect of glucocorticoid administration
is profoundly anti-inflammatory and
immunosuppressive.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

GLUCOCORTICOIDS:

ANTI-INFLAMMATORY MOA

A

• Glucocorticoids relieve pain due to the modulation
of inflammatory responses.
• Glucocorticoids suppress several inflammatory
pathways.
• Glucocorticoids inhibit prostaglandin synthesis
through independent mechanisms:
• Inhibition of PLA2
• Reduction of transcription of COX-2

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

GLUCOCORTICOIDS: ADVERSE EFFECTS?

A

• Short-term use: hypertension, hyperglycemia,
immunosuppression, psychotic reactions, and
cognitive impairment.
• Long-term use: myopathy, Cushing’s syndrome,
and osteoporosis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

GLUCOCORTICOIDS: USES?

A

• Used to prevent and treat transplant rejection.
• Used to treat autoimmune disorders such as
rheumatoid arthritis, SLE, psoriasis, asthma, and
IBD.
• In palliative care glucocorticoids are used to
alleviate pain, nausea, and fatigue.
• Used to treat pain, including neuropathic and bone pain. Dexamethasone is usually preferred because of its long half-life and low mineralocorticoid
effects.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

List 2 Calcineurin inhibitors?

A
  • Cyclosporine

* Tacrolimus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Cyclosporine moa?

A
• Calcineurin is a phosphatase necessary for activation of a Tcell-specific transcription factor: NFAT.
• NFAT is required for the
induction of cytokine genes.
• Cyclosporine forms a
complex with cyclophilin, an
immunophilin.
• This complex inhibits
calcineurin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Cyclosporine AE?

A

• Main adverse reactions: Nephrotoxicity, tremor,
hypertension, hyperglycemia, hyperlipidemia,
osteoporosis, hirsutism, gum hyperplasia.
• Nephrotoxicity is limiting and occurs in the
majority of patients treated. Major indication
for cessation of therapy.
• Very little bone marrow toxicity.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Cyclosporine drug interactions and uses?

A

• Primarily metabolized by CYP3A4: involved in
many drug interactions.

uses:
• Organ transplantation
• Uveitis
• Rheumatoid arthritis
• Psoriasis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Tacrolimus moa?

A
  • Tacrolimus binds to FK-binding protein (FKBP).
  • FKBP is an immunophilin.
  • The tacrolimus-FKBP complex inhibits calcineurin.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Tacrolimus AE?

A
  • Nephrotoxicity
  • Neurotoxicity
  • Hyperglycemia
  • Hypertension
  • Hyperkalemia
  • GI complaints
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

TACROLIMUS: USES?

A

• Prevention of rejection of transplanted kidneys,
liver or heart.
• Topical formulation is used for atopic dermatitis
and psoriasis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

SIROLIMUS category and moa?

A

PROLIFERATION SIGNAL INHIBITORS

• Structurally similar to tacrolimus.
• Sirolimus binds to FKBP.
• But the sirolimus-FKBP complex does not inhibit
calcineurin.
• Instead, it inhibits the serine-threonine kinase
mTOR.
• Blockade of mTOR blocks IL-2-driven T-cell
proliferation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Sirolimus AE?

A
• Myelosuppression
• Hepatotoxicity
• Diarrhea
• Hypertriglyceridemia
• Pneumonitis
• Headache.
• Nephrotoxicity is less common than with
calcineurin inhibitors.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Sirolimus uses?

A

• Renal transplantation.
• Sirolimus-eluting coronary stents are used to
inhibit restenosis of the blood vessels in patients
with severe CAD by reducing cell proliferation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Thalidomide category, actions, and uses?

A

INHIBITORS OF ANGIOGENESIS

  • Its mechanism of action is unclear.
  • Inhibits synthesis of TNF-α.
  • Inhibits angiogenesis.
  • Thalidomide is now called an immunomodulatory drug.
  • Indicated for the treatment of patients with erythema nodosum leprosum and multiple myeloma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Two categories falling under cytotoxic agents?

A
  • ANTIMETABOLITES

* ALKYLATING AGENTS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Name 4 antimetabolites?

A
  • Azathioprine
  • Methotrexate
  • Mycophenolate mofetil
  • Leflunomide
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

AZATHIOPRINE: ADVERSE EFFECTS?

A
  • Bone marrow suppression
  • GI disturbances
  • Increase in infections and malignancies
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Azathioprine moa?

A

• Purine antimetabolite.
• Prodrug of 6-mercaptopurine.
• Converted to 6-MP.
• 6-MP is converted to metabolites that inhibit de
novo purine nucleotide synthesis.
• This leads to suppression of B and T cell
function, of immunoglobulin production and of
IL-2 secretion.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

AZATHIOPRINE: DRUG INTERACTIONS?

A

• Much of the drug’s inactivation depends on
xanthine oxidase.
• Patients who are also receiving allopurinol for
control of hyperuricemia should have the dose of
azathioprine reduced.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

AZATHIOPRINE: USES?

A
  • Prevention of organ transplant rejection

* Severe rheumatoid arthritis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Methotrexate moa?

A

• Methotrexate’s main mechanism of action at the
low doses used in rheumatic diseases is inhibition of aminoimidazolecarboxamide
ribonucleotide (AICAR) transformylase
• AICAR transformylase catalyzes the penultimate
and final steps in de novo purine biosynthesis
which lead to synthesis of IMP.
• Inhibition of AICAR transformylase leads to
accumulation of AMP.
• AMP is released and converted extracellularly to
adenosine
• Adenosine is a potent inhibitor of inflammation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

METHOTREXATE: ADVERSE EFFECTS?

A
  • Nausea
  • Mucosal ulcers
  • Leukopenia
  • Anemia
  • GI ulcerations
  • Hepatotoxicity
  • Cirrhosis is rare.
  • Hypersensitivity pneumonitis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Methotrexate contraindicated and how to reduce toxicity?

A

• Methotrexate toxicity can be reduced with
leucovorin or folic acid.
• Methotrexate is contraindicated in pregnancy.

26
Q

METHOTREXATE: USES?

A
  • Rheumatoid arthritis
  • Psoriasis
  • Psoriatic arthritis
  • Ankylosing spondylitis
  • Systemic lupus erythematosus
27
Q

MYCOPHENOLATE MOFETIL moa?

A

• Mycophenolate mofetil is converted into
mycophenolic acid.
• Mycophenolic acid inhibits inosine
monophosphate dehydrogenase, an enzyme in
the de novo pathway of guanosine triphosphate
(GTP) synthesis.

28
Q

Mycophenolate mofetil action?

A

• This action suppresses both B- and Tlymphocyte activation.
• Lymphocytes are particularly susceptible to
inhibitors of the de novo pathway because they
lack the enzymes necessary for the salvage
pathway.

29
Q

MYCOPHENOLATE MOFETIL:

ADVERSE EFFECTS

A
  • Nausea, vomiting, diarrhea, abdominal pain.
  • Headache
  • Hypertension
  • Reversible myelosuppression
30
Q

MYCOPHENOLATE MOFETIL: USES?

A
  • Prophylaxis of transplant rejection.

* SLE.

31
Q

LEFLUNOMIDE moa?

A
• Prodrug of teriflunomide.
• Teriflunomide inhibits dihydroorotate
dehydrogenase.
• This decreases levels of UMP.
• UMP is essential for the synthesis of pyrimidines.
32
Q

LEFLUNOMIDE: ADVERSE EFFECTS?

A
  • Diarrhea.
  • Reversible alopecia
  • Rash
  • Myelosuppression
  • Increases in aminotransferase activity.
  • CBC and liver function tests should be monitored.
  • Carcinogenic and teratogenic in animals.
  • Contraindicated in pregnancy.
33
Q

LEFLUNOMIDE: USES?

A
  • Rheumatoid arthritis
  • SLE
  • Myasthenia gravis
34
Q

Cyclophosphamide category and action?

A

ALKYLATING AGENTS

• Cyclophosphamide is one of the most effective
immunosuppressive drugs available.
• Cyclophosphamide destroys proliferating
lymphoid cells.
• It also alkylates DNA and other molecules in
resting cells.

35
Q

CYCLOPHOSPHAMIDE: ADVERSE EFFECTS?

A
• Infertility
• Bone marrow suppression
• Hemorrhagic cystitis
• Rarely, bladder carcinoma.
• Acrolein, a metabolite, is responsible for the
urinary toxicities.
• Long-term use increases the risk of infection and
malignancy.
36
Q

CYCLOPHOSPHAMIDE: USES?

A

• Used to treat SLE and other autoimmune diseases.

37
Q

HYDROXYCHLOROQUINE moa and ae?

A

• Mechanism of anti-inflammatory action is
unclear.

AE:
• Serious adverse effects are rare.
• Hemolysis in patients with G6PD deficiency.
• Retinal damage: vision should be monitored.

38
Q

HYDROXYCHLOROQUINE: USES?

A

• Moderately effective for mild rheumatoid arthritis.
• Usually well tolerated.
• Often used with other drugs, particularly
methotrexate and sulfasalazine.
• Also used for lupus erythematosus.
• May require 3-6 months to show clinical benefit

39
Q

SULFASALAZINE constituents and metabolic activation?

A

• Sulfasalazine consists of sulfapyridine and 5-
aminosalicylic (5-ASA) connected by a diazo
bond.
• Metabolized by bacteria in the colon to the
constituent moieties.
• The sulfapyridine is probably the active moiety in the treatment of rheumatoid arthritis.
• The 5-ASA moiety is thought to be important in
ulcerative colitis.

40
Q

SULFASALAZINE: ADVERSE EFFECTS?

A
  • Nausea, vomiting.
  • Headache, rash.
  • Neutropenia.
  • Thrombocytopenia is very rare.
  • Drug-induced lupus is rare.
  • Hemolysis in patients with G6PD deficiency.
41
Q

SULFASALAZINE: USES?

A
  • Ulcerative colitis
  • Rheumatoid arthritis
  • Crohn’s disease
  • Ankylosing spondylitis
42
Q

Name 2 polyclonal antibodies?

A
  • Antilymphocyte & Antithymocyte Antibodies

* Rho(D) Immune Globulin

43
Q

• Two types of antisera directed against
lymphocytes are available:

uses?

A
  • Antilymphocyte globulin (ALG)
  • Antithymocyte globulin (ATG)
  • Used for stem cell transplantation.
  • Also used for solid organ transplantation.
44
Q

RHO(D) IMMUNE GLOBULIN preparation and use?

A

• Rho (D) immune globulin is a preparation of
human IgG containing antibodies against the
Rho
(D) antigen of the red cell.
• Used for prevention of Rh hemolytic disease of
the newborn.

45
Q

MONOCLONAL ANTIBODIES

A
  • TNF-alpha INHIBITORS

* OTHER MONOCLONAL ANTIBODIES

46
Q

Lst three tnf-alpha inhibitors?

MOA?

A
  • Adalimumab
  • Infliximab
  • Etanercept

• TNF-α inhibitors bind to TNF-α and prevent its
interaction with its receptors.

47
Q

TNF-alpha INHIBITORS: ACTIONS?

A

• Blocking TNF-α action results in suppression of
inflammatory cytokines and adhesion molecules
involved in leukocyte activation and migration.

48
Q

Overview adalimumab and uses?

A
• Fully human IgG1 anti-TNF
monoclonal antibody.
USES
• Rheumatoid arthritis
• Psoriatic arthritis
• Ankylosing spondylitis
• Crohn's disease
• Ulcerative colitis
49
Q

Overview of inflimab and uses?

A
• Chimeric monoclonal antibody.
USES
• Rheumatoid arthritis
• Psoriatic arthritis
• Ankylosing spondylitis
• Crohn's disease
• Ulcerative colitis
50
Q

Overview and uses of Etanercept?

A
• Not a true Mab.
• Contains the ligand-binding portion of human TNF-α receptor fused to Fc portion of human IgG1.
USES
• Rheumatoid arthritis
• Ankylosing spondylitis
• Psoriatic arthritis
51
Q

ANTI-TNF-alpha DRUGS: ADVERSE EFFECTS

A

• Cytopenias can occur. CBC should be monitored.
• TNF inhibitors increase risk of infections.
• TNF inhibitors should not be given to patients with
an active infection.
• Live vaccinations should not be given to patients
on TNF inhibitor therapy.
• Patients should be screened for TB and HBV
infection.
• TNF inhibitors may increase risk of malignancies.
• TNF inhibitors may increase risk of GI ulcers and
large bowel perforation.
• TNF inhibitors can induce formation of anti-drug
antibodies. These antibodies may interfere with
drug efficacy and correlate with infusion site
reactions.
• TNF inhibitors can exacerbate HF.

52
Q

Omalizumab moa and use?

A

• Anti-IgE recombinant humanized monoclonal
antibody.
• Binds to IgE and prevents IgE from binding to
mast cells and basophils, thereby preventing
release of inflammatory mediators after allergen
exposure.
• Used in asthma refractory to inhaled corticoids
and evidence of allergic sensitization.
• Also approved for chronic urticaria.

53
Q

Basiliximab moa and use?

A
  • IL-2 receptor antagonist.
  • Chimeric human-mouse IgG.
  • Binds to the IL-2 receptor.
  • Used to prevent renal transplant rejection.
54
Q

Rituximab moa and uses?

A

• Chimeric murine-human monoclonal antibody that
binds to the CD20 molecule on B lymphocytes.
• Causes depletion of circulating B cells.
• Used for treatment of non-Hodgkin’s lymphoma and
chronic lymphocytic leukemia.
• Also approved for the treatment of rheumatoid
arthritis.

55
Q

Anakinra action and uses?

A

• IL-1 receptor antagonist.
• Recombinant version of the naturally occurring
human IL-1RA that prevents IL-1 from binding to its
receptor.
• Approved for moderate to severe rheumatoid
arthritis.

56
Q

ABATACEPT overview and use?

A
  • Fusion protein that interferes with T-cell activation.

* Used for moderate to severe rheumatoid arthritis.

57
Q

List 3 immunostimulants?

A
  • Aldesleukin
  • Interferons
  • Bacillus Calmette-Guérin (BCG)
58
Q

ALDESLEUKIN structure and use?

A

• Recombinant interleukin-2 (IL-2).
• Indicated for treatment of renal cell carcinoma
and malignant melanoma.

59
Q

Interferons alpha, beta, and gamma uses?

A

• Interferon-alpha is used in hairy cell leukemia,
chronic myelogenous leukemia, malignant
melanoma, Kaposi’s sarcoma, and hepatitis B
and C infections.
• Interferon-beta is approved for use in relapsing
multiple sclerosis.
• Interferon-gamma is approved for treatment of chronic
granulomatous disease.
106
BACILLUS CALMETTE-GUÉRIN

60
Q

BACILLUS CALMETTE-GUÉRIN (BCG) uses and ae?

A

• Attenuated, live culture of Mycobacterium bovis.
• By unclear mechanisms, it is active against
tumors.
• It is indicated for the treatment and prophylaxis
of carcinoma of the urinary bladder.
• Adverse effects include hypersensitivity, shock,
chills, fever, malaise, and immune complex
disease.